News | February 10, 2008

Third Generation Heart Valve Improves Flow, Survival

February 11, 2008 - Leman Cardiovascular’s animal studies to evaluate the performance in both the aortic and mitral positions of its heart valve resulted in energy loss in blood cardiac throughput and a 100 percent survival rate at 90 days, an approach that may rival stented valves.

The LCV heart valve is designed to maximize blood flow and is said to require less work to accommodate any given cardiac output. The internal supports are placed in a manner to achieve a restoration of the native anatomy at the inflow of the valve; this allows the stress-free preserved leaflets to function in a manner mimetic of a natural valve. The new data shows that animals in which the LCV valve was implanted show an average of 120 percent increase in hemodynamic studies over existing stented valves.

"The animal study results are really very encouraging and show the product holds strong promise," said Professor R. Bianco, head of the Experimental Surgical Department of the University of Minnesota. Professor Bianco has no conflict of interest with Leman

For more information: www.lemancardiovascular.com and www.hancockjaffe.com

Related Content

First TriCinch Coil Tricuspid Repair Systems Implanted in U.S.
News | Heart Valve Technology | November 06, 2018
4Tech Inc. initiated its U.S. Early Feasibility Study of the TriCinich Coil System following U.S. Food and Drug...
Valve Replacement Volume Key to Successful Patient Outcomes
News | Heart Valve Technology | November 02, 2018
Hospitals that routinely perform a heart valve replacement procedure requiring open heart surgery are more likely to...
Prosthetic Valve Mismatches Common in TAVR Procedures
News | Heart Valve Technology | October 03, 2018
A high number of patients in a study who underwent transcatheter aortic valve replacement (TAVR) experienced severe and...
Local Anesthesia Safe and Effective for Intermediate- and High-Risk TAVR Patients
News | Heart Valve Technology | September 28, 2018
The first randomized study to compare general versus local anesthesia during transcatheter aortic valve replacement (...
MitraClip Reduces Mortality for Heart Failure Patients With Secondary Mitral Regurgitation
News | Heart Valve Technology | September 26, 2018
Patients with heart failure and secondary mitral regurgitation (MR) who remained symptomatic despite maximally...
Ancora Heart Announces Positive Interim Analysis of AccuCinch Ventricular Repair System for Heart Failure
News | Heart Valve Technology | September 24, 2018
Ancora Heart Inc. announced positive clinical data from the company’s recently expanded U.S. early feasibility study...
Medtronic Announces TAVR Study of Aortic Stenosis Patients With Bicuspid Valves
News | Heart Valve Technology | September 19, 2018
The U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) to initiate a new...
4C Medical's AltaValve First-in-Human Experience to be Presented at TCT 2018
News | Heart Valve Technology | September 17, 2018
September 17, 2018 — 4C Medical Technologies Inc.
Gore Acquires Pipeline Medical Technologies Inc.
News | Heart Valve Technology | September 06, 2018
W. L. Gore & Associates Inc. (Gore) announced the acquisition of Pipeline Medical Technologies Inc., a privately...
Overlay Init